Logo

American Heart Association

  104
  0


Final ID:

Pro: Andexanet alfa is Preferred over PCC for Reversal of FXa Inhibitor Associated ICH

  • Shoamanesh, Ashkan  ( MCMASTER UNIVERSITY , Hamilton , Ontario , Canada )
  • Goldstein, Joshua  ( MASSACHUSETTS GENERAL HOSPITAL , Lynnfield , Massachusetts , United States )
  • Christensen, Hanne  ( BISPEBJERG HOSPITAL , Copenhagen Nv , Denmark )
  • Seiffge, David  ( Inselspital , Bern , Switzerland )
  • Siegal, Deborah  ( University of Ottawa , Ottawa , Ontario , Canada )
  • Author Disclosures:
    Ashkan Shoamanesh: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now) ; Consultant:Bioxides:Past (completed) ; Speaker:Bayer AG:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:AstraZeneca:Active (exists now) ; Consultant:Bayer AG:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now) | Joshua Goldstein: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:NControl:Past (completed) ; Consultant:Pfizer:Past (completed) ; Individual Stocks/Stock Options:Cayuga:Active (exists now) ; Consultant:Takeda:Active (exists now) ; Consultant:CSL Behring:Past (completed) ; Consultant:Octapharma:Active (exists now) | Hanne Christensen: DO have relevant financial relationships ; Researcher:ANNEXA-I trial Astra-Zeneca:Active (exists now) | David Seiffge: DO NOT have relevant financial relationships | Deborah Siegal: No Answer
Meeting Info:
Session Info:

Fast and Furious: Stroke in the Real World - Addressing Challenges In Acute Stroke Management

Tuesday, 02/04/2025 , 08:30AM - 05:00PM

Pre-Con Symposium – Stroke in the Real World

More abstracts on this topic:
EVT for Mild severity or distal occlusion – what to do pending RCT

Goyal Mayank, Nogueira Raul, Leslie-mazwi Thabele, Nguyen Thanh, Fifi Johanna

Everything but the Kitchen Sink. IVT when patients are destined for EVT (0-4.5 and >4.5h) - What to Use And When?

Asdaghi Negar, Fischer Urs, Coutts Shelagh

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)